2-溴-6-氯-4-(三氟甲氧基)苯胺 | 1228108-74-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-溴-6-氯-4-(三氟甲氧基)苯胺
• 英文名称: 2-bromo-6-chloro-4-(trifluoromethoxy)aniline
• CAS: 1228108-74-4
• 化学式: C₇H₄BrClF₃NO
• 分子量: 290.467
• InChiKey: DIHNAXVPGYEEIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2922299090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-溴-6-氯-4-(三氟甲氧基)苯胺 在 亚硝酸特丁酯 、 copper dichloride 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 1-bromo-2,3-dichloro-5-(trifluoromethoxy)benzene
  参考文献：
  名称：

  [EN] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS
  [FR] COMPOSÉS DE TÉTRAHYDROISOQUINOLINE SUBSTITUÉS UTILES COMME AGONISTES DU GPR120

  摘要：

  本发明涉及一种由公式(I)表示的化合物，以及披露了治疗或预防糖尿病、高脂血症、肥胖、非酒精性脂肪肝炎（NASH）、炎症相关疾病及相关疾病和状况有用的药用可接受盐。这些化合物作为G蛋白偶联受体GPR120的激动剂是有用的。还包含了药物组合物和治疗方法。

  公开号：

  WO2017205193A1

文献信息

• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021123294A1

  公开（公告）日：2021-06-24

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性上行性麻痹；以及伴有tau病理的神经退行性疾病，特别是由C9ORF72突变引起的肌萎缩侧索硬化或额颞叶痴呆。
• Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11161819B2

  公开（公告）日：2021-11-02

  The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

  本发明涉及一种由式 (I) 代表的化合物： 及其药学上可接受的盐，可用于治疗或预防糖尿病、高脂血症、肥胖症、NASH、炎症相关疾病以及相关疾病和病症。这些化合物可作为 G 蛋白偶联受体 GPR120 的激动剂。还包括药物组合物和治疗方法。
• SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3463362A1

  公开（公告）日：2019-04-10
• OGA INHIBITOR COMPOUNDS
  申请人：Janssen Pharmaceutica NV

  公开号：US20210130352A1

  公开（公告）日：2021-05-06

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.